Dose optimization of recombinant factor VIIa for control of mild to moderate bleeds in inhibitor patients: Improved efficacy with higher dosing

被引：20

作者：

Abshire, TC

机构：

[1] Emory Univ, Sch Med, AFLAC Canc & Blood Disorders Serv, Atlanta, GA 30322 USA

[2] Emory Univ, Sch Med, Comprehens Hemophilia Program, Atlanta, GA 30322 USA

来源：

SEMINARS IN HEMATOLOGY | 2004年 / 41卷 / 01期

关键词：

D O I：

10.1053/j.seminhematol.2003.11.002

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：3 / 7

页数：5

共 24 条

[1]

Allen GA, 2002, CAN J ANAESTH, V49, pS7

[2] The effect of factor X level on thrombin generation and the procoagulant effect of activated factor VII in a cell-based model of coagulation [J].

Allen, GA ;

Monroe, DM ;

Roberts, HR ;

Hoffman, M .

BLOOD COAGULATION & FIBRINOLYSIS, 2000, 11 :S3-S7

[3]

[Anonymous], BLOOD COAGUL FIBRINO

[4] FIBRIN IN HUMAN PLASMA - GEL ARCHITECTURES GOVERNED BY RATE AND NATURE OF FIBRINOGEN ACTIVATION [J].

BLOMBACK, B ;

CARLSSON, K ;

FATAH, K ;

HESSEL, B ;

PROCYK, R .

THROMBOSIS RESEARCH, 1994, 75 (05) :521-538

[5] Rationale for the use of high dose rFVIIa in a high-titre inhibitor patient with haemophilia B during major orthopaedic procedures [J].

Cooper, HA ;

Jones, CP ;

Campion, E ;

Roberts, HR ;

Hedner, U .

HAEMOPHILIA, 2001, 7 (05) :517-522

[6] Pharmacokinetics of recombinant activated factor VII (rFVIIa) [J].

Erhardtsen, E .

SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2000, 26 (04) :385-391

[7] Recombinant factor Vlla (NovoSeven®) as a hemostatic agent [J].

Hedner, U .

DM DISEASE-A-MONTH, 2003, 49 (01) :39-48

[8]

Hoffman M, 1998, BLOOD COAGUL FIBRIN, V9, pS61

[9]

Ingerslev J, 1998, BLOOD COAGUL FIBRIN, V9, pS107

[10] A new approach to treatment of bleeding episodes in young hemophilia patients:: a single bolus megadose of recombinant activated factor VII (NovoSeven®) [J].

Kenet, G ;

Lubetsky, A ;

Luboshitz, J ;

Martinowitz, U .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2003, 1 (03) :450-455

← 1 2 3 →